A new diabetes medication has been linked to at least 33 deaths since it was approved in 1996. According to the Los Angeles Times, the government's top diabetes researcher at the National Institutes of Health (NIH) was a paid consultant to Rezulin's manufacturer, Warner-Lambert, while he oversaw the selection and use of the drug in a major government diabetes prevention study. Rep. Waxman wrote NIH Director Dr. Harold Varmus to resolve questions about the safety of Rezulin and the potential conflicts of interest. **Documents and Links**

- Letter to NIH